Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
midomafetamine + palmidrol
- Development stage
- Preclinical
- Lead developer
- Clearmind Medicine
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
mdma + palmitoylethanolamide (CMND-400) is a novel small-molecule combination drug candidate being developed by Clearmind Medicine in collaboration with Neurothera Labs. It consists of 3,4-methylenedioxymethamphetamine (MDMA), a synthetic empathogen, and palmitoylethanolamide (PEA), an endogenous fatty acid amide. The combination is primarily targeted at treating post-traumatic stress disorder (PTSD), anxiety, and eating disorders. MDMA's mechanism of action involves the release of serotonin, norepinephrine, and dopamine by acting on their respective transporters (SERT, NET, and DAT) and activating TAAR1. PEA acts as an agonist of the peroxisome proliferator-activated receptor alpha (PPAR-α) and modulates the endocannabinoid system, providing anti-inflammatory and neuroprotective effects. The inclusion of PEA is intended to enhance the therapeutic efficacy of MDMA while potentially reducing its neurotoxicity and improving the overall safety profile of the treatment.
- Other names
- mdma + palmitoylethanolamideMDMA + PEA3,4-methylenedioxymethamphetamine + palmitoylethanolamide
02
Targets
AR (Adrenergic receptors)SERT (Sodium-dependent serotonin transporter)PPARA (Peroxisome proliferator-activated receptor alpha)HTR2A (Serotonin receptor 5-HT2A)HTR1B (5-Hydroxytryptamine Receptor 1B)HTR1D (5-hydroxytryptamine receptor 1D)TRPV1 (Transient receptor potential cation channel subfamily V member 1)HTR2C (5-hydroxytryptamine 2C receptor)DRD1 (Dopamine D1 Receptor)NET (Norepinephrine Transporter)DAT (Dopamine plasma membrane transport protein)DRD2 (Dopamine D2 Receptor)TAAR1 (Trace amine-associated receptor 1)HTR2B (5-Hydroxytryptamine Receptor 2B)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))
Beyond the preview
Go deeper on midomafetamine + palmidrol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on midomafetamine + palmidrol.